<DOC>
	<DOCNO>NCT00620594</DOCNO>
	<brief_summary>This first-in-human , phase I/Ib clinical research study BEZ235 , inhibitor phosphatidylinositol 3'-kinase ( PI3K ) . The study consist dose escalation part follow safety dose expansion part : Dose escalation part ( advanced solid tumor , include patient breast cancer treat trastuzumab ) : Patients receive oral BEZ235 daily day 1-28 first course . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts least 3 patient receive escalate dos BEZ235 , single agent combination trastuzumab , maximum tolerate dose ( MTD ) determine . The MTD define dose expect produce first course treatment dose-limiting toxicity 33 % patient . Once MTD define , safety expansion part trial open enrollment . Safety dose expansion part ( advanced solid tumor , include patient breast cancer treat trastuzumab ) : Patients treat BEZ235 , single agent combination trastuzumab , give MTD , daily . Treatment patient continue disease progression occurrence unacceptable side effect .</brief_summary>
	<brief_title>A Phase I/II Study BEZ235 Patients With Advanced Solid Malignancies Enriched Patients With Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hamartoma Syndrome , Multiple</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>[ Single agent dose escalation arm ] : Patients histologicallyconfirmed , advance unresectable solid tumor include CS patient progress ( able tolerate ) standard therapy within three month screen visit standard anticancer therapy exist . [ Combination part ] : Patients metastatic HER2+ Breast Cancer , failure trastuzumab treatment . Eligible patient tumor carry molecular alteration PIK3CA and/or PTEN . [ Single agent safety expansion arm ] : Patients histologicallyconfirmed , advance unresectable solid tumor include CS patient progress ( able tolerate ) standard therapy within three month screen visit standard anticancer therapy exists . Patients prescreened molecular alteration affect PIK3CA and/or PTEN . Patients NSCLC also prescreened EGFR mutation . Patients brain metastasis , progressive and/or require medical intervention symptom control Prior treatment PI3K inhibitor Acute chronic liver disease renal disease Acute chronic pancreatitis Patients unresolved diarrhea â‰¥ CTCAE grade 2 Impaired cardiac function clinically significant cardiac disease Patients diabetes mellitus require insulin treatment Patients known coagulopathies Patients history photosensitivity reaction drug Any follow ophthalmological finding : Progressive eye disease could lead severe loss visual acuity visual field loss study period Inability perform ophthalmic procedure require protocol Other concurrent severe and/or uncontrolled concomitant medical condition ( e.g . active uncontrolled infection ) could cause unacceptable safety risk compromise compliance protocol . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Neoplasms</keyword>
	<keyword>breast neoplasm</keyword>
	<keyword>breast disease</keyword>
	<keyword>solid tumor</keyword>
	<keyword>BEZ235</keyword>
	<keyword>breast cancer</keyword>
	<keyword>PI3K Inhibitor</keyword>
	<keyword>Phosphatidylinositol 3</keyword>
	<keyword>kinase</keyword>
	<keyword>advanced</keyword>
</DOC>